4,318,109 Shares in Alector, Inc. $ALEC Purchased by Nantahala Capital Management LLC

Nantahala Capital Management LLC acquired a new position in Alector, Inc. (NASDAQ:ALEC) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 4,318,109 shares of the company’s stock, valued at approximately $8,679,399.

Several other large investors have also bought and sold shares of the company. Bronte Capital Management Pty Ltd. purchased a new position in shares of Alector during the 4th quarter worth approximately $30,000. Prudential Financial Inc. purchased a new position in shares of Alector in the 2nd quarter valued at approximately $30,000. Hershey Trust Co. lifted its stake in shares of Alector by 100.0% in the 4th quarter. Hershey Trust Co. now owns 20,572 shares of the company’s stock valued at $32,000 after purchasing an additional 10,286 shares during the period. Virtu Financial LLC bought a new stake in shares of Alector during the fourth quarter valued at approximately $34,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Alector during the second quarter valued at approximately $39,000. 85.83% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ALEC has been the topic of several recent research reports. Wall Street Zen raised Alector from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings raised Alector from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Finally, Morgan Stanley restated an “underweight” rating and set a $2.00 target price on shares of Alector in a report on Monday, May 4th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Alector currently has a consensus rating of “Hold” and an average price target of $3.62.

Insider Buying and Selling

In other Alector news, CEO Arnon Rosenthal sold 87,216 shares of Alector stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $1.97, for a total transaction of $171,815.52. Following the completion of the transaction, the chief executive officer owned 2,367,206 shares in the company, valued at approximately $4,663,395.82. The trade was a 3.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Neil Lindsay Berkley sold 19,360 shares of the business’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $1.97, for a total value of $38,139.20. Following the completion of the sale, the chief financial officer directly owned 379,900 shares in the company, valued at $748,403. This trade represents a 4.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 115,760 shares of company stock valued at $227,734. 8.30% of the stock is owned by corporate insiders.

Alector Price Performance

Shares of NASDAQ ALEC opened at $2.34 on Friday. The company has a 50 day simple moving average of $1.84 and a two-hundred day simple moving average of $2.04. Alector, Inc. has a fifty-two week low of $1.09 and a fifty-two week high of $3.40. The company has a market capitalization of $261.28 million, a price-to-earnings ratio of -2.13 and a beta of 0.60. The company has a debt-to-equity ratio of 0.80, a quick ratio of 5.26 and a current ratio of 5.26.

Alector (NASDAQ:ALEC) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. The firm had revenue of $3.32 million for the quarter, compared to analysts’ expectations of $1.71 million. Alector had a negative return on equity of 531.03% and a negative net margin of 850.13%. Analysts expect that Alector, Inc. will post -0.87 EPS for the current fiscal year.

Alector Profile

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.